The Binding of Thyroid Transcription Factor-1 and Hepatocyte Paraffin 1 to Mitochondrial Proteins in Hepatocytes

Pang, Yanbo; Turkovich, Michele von; Wu, Hui; Mitchell, Jeannette; Mount, Sharon L.; Taatjes, Douglas J.; Cooper, Kumarasen

doi:10.1309/ebcb-6h54-k1n2-p9ql

Cited by 10 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75 The different cellular and structural antigenic targets, broad spectrum of clinical situations in which IHC is used, and the lack of consistent, reliable, external and internal control standards, makes this an unrealistic goal. [97][98][99] In the absence of a universal IHC assay scoring system, responsibility rests with the pathologist to provide this information in the report. It is important that pathologists understand the transport pathways of these proteins and restrict interpretation to the relevant subcellular structures as reported in the literature by that specific antibody clone.…”

Section: Commentsmentioning

confidence: 99%

Recommendations for Improved Standardization of Immunohistochemistry

Goldstein

Hewitt

Taylor

et al. 2007

Applied Immunohistochemistry &Amp; Molecular Morphology

201

118

View full text Add to dashboard Cite

Immunohistochemistry (IHC) continues to suffer from variable consistency, poor reproducibility, quality assurance disparities, and the lack of standardization resulting in poor concordance, validation, and verification. This document lists the recommendations made by the Ad-Hoc Committee on Immunohistochemistry Standardization to address these deficiencies. Contributing factors were established to be underfixation and irregular fixation, use of nonformalin fixatives and ancillary fixation procedures divested from a deep and full understanding of the IHC assay parameters, minimal or absent IHC assay optimization and validation procedures, and lack of a standard system of interpretation and reporting. Definitions and detailed guidelines pertaining to these areas are provided.

show abstract

Section: Commentsmentioning

confidence: 99%

Recommendations for Improved Standardization of Immunohistochemistry

Goldstein

Hewitt

Taylor

et al. 2007

Applied Immunohistochemistry &Amp; Molecular Morphology

201

118

View full text Add to dashboard Cite

show abstract

“…20 In that study, Western blot analysis with cellular proteins extracted from normal human liver demonstrated that Hep Par 1 and TTF-1 bound to a protein band of approximately 150 kd. The authors speculated that different epitopes to Hep Par 1 and TTF-1 share the same protein molecules in hepatocyte mitochondria, and we completely agree.…”

Section: Discussionmentioning

confidence: 89%

Cytoplasmic Immunoreactivity of Thyroid Transcription Factor-1 (Clone 8G7G3/1) in Hepatocytes

Gu¹,

Shah²,

Ma³

et al. 2007

Am J Clin Pathol

View full text Add to dashboard Cite

The nuclear immunoreactivity for thyroid transcription factor-1 (TTF-1) is a useful marker for identification of carcinomas of thyroid and lung origin. Our aim was to determine whether cytoplasmic staining in the liver is a result of cross-reaction of anti-TTF-1 antibody (clone 8G7G3/1, DAKO, Carpinteria, CA) or true positivity resulting from aberrant expression of TTF-1 or products of the alternatively sliced TTF-1 gene. Fresh tissue samples from liver, thyroid, and lung were obtained for H&E-stained sections, TTF-1 immunostaining, and RNA and protein analyses. Western blot revealed an abundant band corresponding to an approximately 160-kd protein from liver but not either thyroid or lung tissue samples. By reverse transcriptase-polymerase chain reaction, messenger RNA of TTF-1 was not detectable in liver tissue. Our study demonstrates that TTF-1 immunoreactivity (clone 8G7G3/1) in the hepatocyte cytoplasm is due to an approximately 160-kd protein; this unique protein is not an alternative splicing product of TTF-1 and neither is it expressed in thyroid and lung tissues.

show abstract

“…Hepatocyte paraffin-1 (HepPar-1) is a mouse monoclonal antibody that reacts with a poorly characterized antigen present in hepatocytes, probably within mitochondria 63 . However, studies have also shown that HepPar-1 can be expressed in carcinomas from the pancreatobiliary tree, the tubular gastrointestinal tract, lung and genitourinary tract 64 .…”

Section: Discussionmentioning

confidence: 99%

Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas

et al. 2016

View full text Add to dashboard Cite

Intraductal oncocytic papillary neoplasm(IOPN) of the pancreas is classified as a variant of intraductal papillary mucinous neoplasm(IPMN) in the WHO guidelines. However, the neoplastic cells of IOPNs are unique, with distinctive architecture/oncocytic cytoplasm. Although molecular/immunohistochemical features of other IPMN variants have been extensively studied, those of IOPNs have not been well characterized. Expression profile of antibodies associated with genetic alterations previously described for ductal adenocarcinomas(DAs) and IPMNs(SMAD4/β-catenin/p53/mesothelin/claudin-4) as well as with antibodies to mucins and differentiation markers(MUC1/MUC2/MUC5AC/MUC6/CDX2/HepPar-1) was investigated in 24 IOPNs and 22 IPMNs to assess the similarities/differences between these tumors. Expression of mesothelin and claudin-4 were dissimilar between these tumor types: a higher proportion of IOPNs labeled with mesothelin[21/24(87.5%) of IOPNs, 6/22(27%) of IPMNs, p<0.001], while the reverse was true for claudin-4[2/23(9%) of IOPNs, 9/22(41%) of IPMNs, p=0.01]. The results of immunolabeling for SMAD4/β-catenin/p53 were similar in both: None of the cases showed SMAD4 loss in the intraductal components and only 1/21(5%) of IOPNs and 2/22(9%) of IPMNs revealed abnormal β-catenin expression(p=0.49). Nuclear p53 accumulation was seen mostly in architecturally complex/high grade dysplasia areas in both. Immunolabeling for MUC proteins showed that almost all lesions expressed MUC5AC. 12/24(50%) of IOPNs and 6/22(27%) of IPMNs(p=0.11) labeled for MUC1, whereas 7/24(29%) of IOPNs and 10/22(45%) of IPMNs labeled for MUC2(p=0.25). MUC6 was expressed in 8/9(89%) of IOPNs(strong) and 6/21(29%) of IPMNs(weak)(p=0.002). 14/23(61%) of IOPNs and 4/22(18%) of IPMNs labeled for HepPar-1(p=0.003). These results show that IOPNs have distinct immunoprofile and provide support for the proposition that IOPN is a distinct entity developing through a mechanism different from other pancreatic ductal neoplasms.

show abstract

The Binding of Thyroid Transcription Factor-1 and Hepatocyte Paraffin 1 to Mitochondrial Proteins in Hepatocytes

Cited by 10 publications

References 19 publications

Recommendations for Improved Standardization of Immunohistochemistry

Recommendations for Improved Standardization of Immunohistochemistry

Cytoplasmic Immunoreactivity of Thyroid Transcription Factor-1 (Clone 8G7G3/1) in Hepatocytes

Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas

Contact Info

Product

Resources

About